Aclaris Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

MALVERN, Pa., Oct. 13, 2015 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (Nasdaq:ACRS) today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a price to the public of $11.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock. All of the shares in the offering were offered by Aclaris. The aggregate net proceeds to Aclaris, after underwriting discounts and commissions and estimated offering expenses, are expected to be $56.5 million. The common stock began trading on The NASDAQ Global Select Market on October 7, 2015 under the ticker symbol “ACRS.”

Jefferies LLC and Citigroup Global Markets Inc. acted as joint book-running managers for the offering. William Blair & Company, L.L.C. acted as a co-manager.

The offering was made only by means of a prospectus. A copy of the final prospectus relating to these securities may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340 or by email at prospectus_department@jefferies.com, or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (800) 831-9146, or by email at prospectus@citi.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 6, 2015.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania.

CONTACT: Aclaris Contact
         Frank Ruffo
         Chief Financial Officer
         484-324-7933
         investors@aclaristx.com
         
         Investor Contact
         Patricia L. Bank
         Westwicke Partners
         Managing Director
         415-513-1284
         patti.bank@westwicke.com
         
         Media Contact
         Mike Beyer
         Sam Brown, Inc.
         312-961-2502
         mikebeyer@sambrown.com